Abivax Drops 32% On Cancer Signal: Jefferies Warns Of ‘Real’ Overhang But Retail Calls Selloff An ‘Overreaction’
Jefferies downgraded Abivax to ‘Hold’ from ‘Buy’ and slashed the price target to $90 from $160, a 30% potential downside from the stock’s closing price on Monday. Abivax said its late-stage trial to treat ulcerative colitis showed strong results. However, there was a small number of reported skin cancer cases and other malignancies in the higher-dose group.
How this was made
The 30-second read
Why it matters
The new safety signal triggered a sell-side downgrade and a large price-target cut, reinforcing investor concerns about durability of the program’s risk-benefit profile and extending uncertainty into the next year.
Market read
Traders are likely to focus on how the market prices the probability and severity of a causal safety issue versus the magnitude of efficacy, with near-term volatility driven by the downgrade and premarket repricing.
What to watch
Abivax claims the malignancies were rare, mainly in older patients, and unrelated to treatment, which could reduce the probability of a true causal safety liability if corroborated by further analysis.
Background
Abivax reported late-stage ulcerative colitis results for Obefazimod with strong remission rates, but disclosed a small number of skin cancer and other malignancies in the higher-dose group.
Ticker impact
Jefferies downgraded Abivax to Hold and cut its price target to $90 after the ulcerative colitis trial’s cancer signal.
Bearish bias for the next sessions as investors reprice the safety signal and wait for future catalysts.
The article ties the downgrade and target cut directly to the reported skin cancer and malignancies in the higher-dose group, and notes no major data catalysts expected over the next year.
Market effects
Highlights how oncology-safety signals in immunology/IBD programs can quickly reset risk premiums for biotech late-stage assets.
Limited, primarily US premarket sentiment for a US-listed biotech ADR.
Moderate for global biotech risk appetite, but the catalyst is company-specific.
Counterpoint
Citizens kept an Outperform rating and argued efficacy was far above expectations, implying the cancer events may be rare and not treatment-related.
Key entities
- companyAbivax
Late-stage ulcerative colitis program Obefazimod; shares fell after a cancer-related signal and a Jefferies downgrade.
- analyst_firmJefferies
Downgraded Abivax to Hold from Buy and cut the price target to $90 from $160.
- analyst_firmCitizens
Raised price target to $187 from $131 and maintained Outperform despite the safety update.
